Treatment of Refractory Helicobacter pylori Infection-Tailored or Empirical Therapy

키워드

참고문헌 (68)

1. Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
2. Lee YC, "Association between Helicobacter pylori eradication and gastric cancer incidence : a systematic review and meta-analysis", Gastroenterology, 150, pp.1113~1124 (2016)
3. Liou JM, "pylori eradication for gastric cancer prevention", Cancers(Basel), 11, pp.593~ (2019)
4. Liou JM, "Screening and eradication of Helicobacter pylori for gastric cancer prevention : the Taipei global consensus", Gut, 69, pp.2093~2112 (2020)
5. Graham DY, "Helicobacter pylori update : gastric cancer, reliable therapy, and possible benefits", Gastroenterology, 148, pp.719~731 (2015)
6. Kuo YT, "Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 2, pp.707~715 (2017)
7. Liou JM, "Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection : a randomised comparative trial with crossover design", Gut, 59, pp.572~578 (2010)
8. Fallone CA, "The Toronto Consensus for the treatment of Helicobacter pylori infection in adults", Gastroenterology, 151, pp.51~69 (2016)
9. Liou JM, "Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of Helicobacter pylori : a randomized trial", Am J Gastroenterol, 111, pp.381~387 (2016)
10. Liou JM, "Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection : a multicentre clinical trial", J Antimicrob Chemother, 66, pp.1847~1852 (2011)
11. Blaser MJ, "Antibiotic use and its consequences for the normal microbiome", Science, 352, pp.544~545 (2016)
12. Liou JM, "Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication : a multicentre, open-label, randomised trial", Lancet Infect Dis, 19, pp.1109~1120 (2019)
13. Vakil N, "Eradication therapy for Helicobacter pylori", Gastroenterology, 133, pp.985~1001 (2007)
14. Liou JM, "The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors : a nationwide study", PLoS One, 10, pp.e0124199~ (2015)
15. Liou JM, "Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin-and clarithromycin-based therapies", Antimicrob Agents Chemother, 55, pp.1123~1129 (2011)
16. Cammarota G, "Review article : biofilm formation by Helicobacter pylori as a target for eradication of resistant infection", Aliment Pharmacol Ther, 36, pp.222~230 (2012)
17. Fontes LES, "Nacetylcysteine as an adjuvant therapy for Helicobacter pylori eradication", Cochrane Database Syst Rev, 2, pp.CD012357~ (2019)
18. Graham DY, "Hp-normogram(normo-graham)for assessing the outcome of H. pylori therapy : effect of resistance, duration, and CYP2C19 genotype", Helicobacter, 21, pp.85~90 (2016)
19. Graham DY, "Relative potency of protonpump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI", Helicobacter, 24, pp.e12554~ (2019)
20. Liou JM, "Sequential versus triple therapy for the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial", Lancet, 381, pp.205~213 (2013)
21. Liou JM, "Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations : a randomised trial", Gut, 65, pp.1784~1792 (2016)
22. Yuan Y, "Optimum duration of regimens for Helicobacter pylori eradication", Cochrane Database Syst Rev, (12), pp.CD008337~ (2013)
23. Liou JM, "Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial", Lancet, 388, pp.2355~2365 (2016)
24. McNicholl AG, "Meta-analysis : esomeprazole or rabeprazole vs. firstgeneration pump inhibitors in the treatment of Helicobacter pylori infection", Aliment Pharmacol Ther, 36, pp.414~425 (2012)
25. Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
26. Liou JM, "14 day sequential therapy versus 10 day bismuth quadruple therapy containing highdose esomeprazole in the first-line and second-line treatment of Helicobacter pylori : a multicentre, non-inferiority, randomized trial", J Antimicrob Chemother, 73, pp.2510~2518 (2018)
27. Graham DY, "Antibiotic resistance in Helicobacter pylori : implications for therapy", Gastroenterology, 115, pp.1272~1277 (1998)
28. Graham DY, "Interchangeable use of proton pump inhibitors based on relative potency", Clin Gastroenterol Hepatol, 16, pp.800~808 (2018)
29. Liou JM, "Toward population specific and personalized treatment of Helicobacter pylori infection", J Biomed Sci, 25, pp.70~ (2018)
30. 노형민, "Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice", 대한소화기학회지, 68(5), pp.260~264 (2016), 대한소화기학회
31. Sue S, "Randomized trial of vonoprazan-based versus proton-pump inhibitor-based thirdline triple therapy with sitafloxacin for Helicobacter pylori", J Gastroenterol Hepatol, 34, pp.686~692 (2019)
32. Yang JC, "High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection", Clin Gastroenterol Hepatol, 13, pp.895~905 (2015)
33. Chen MJ, "Systematic review with meta-analysis : concomitant therapy vs. triple therapy for the first-line treatment of Helicobacter pylori infection", Am J Gastroenterol, 113, pp.1444~1457 (2018)
34. Puig I, "Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection", Int J Clin Pract, 71, pp.e13004~ (2017)
35. Chen PY, "Systematic review with meta-analysis : the efficacy of levofloxacin triple therapy as the first-or second-line treatments of Helicobacter pylori infection", Aliment Pharmacol Ther, 44, pp.427~437 (2016)
36. Hsu PI, "Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures", Eur J Clin Invest, 38, pp.404~409 (2008)
37. Ciccaglione AF, "Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection : two pilot studies", Helicobacter, 21, pp.375~381 (2016)
38. Gasbarrini A, "Efficacy of a multistep strategy for Helicobacter pylori eradication", Aliment Pharmacol Ther, 14, pp.79~83 (2000)
39. Vicente R, "Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures : a prospective cultureguided study", Gastroenterol Hepatol, 25, pp.438~442 (2002)
40. Cammarota G, "High efficacy of 1-week doxycycline-and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection", Aliment Pharmacol Ther, 19, pp.789~795 (2004)
41. Yahav J, "Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure", Dig Dis Sci, 51, pp.2316~2321 (2006)
42. Tay CY, "Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations", Aliment Pharmacol Ther, 36, pp.1076~1083 (2012)
43. Fiorini G, "Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection", Clin Gastroenterol Hepatol, 11, pp.507~510 (2013)
44. Liou JM, "Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection : a multicentre clinical trial", J Antimicrob Chemother, 68, pp.450~456 (2013)
45. Costa S, "Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection", Eur J Gastroenterol Hepatol, 29, pp.1258~1263 (2017)
46. Liou JM, "Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection", Gastroenterology, 155, pp.1109~1119 (2018)
47. Yu L, "Susceptibility-guided therapy for Helicobacter pylori infection treatment failures", Therap Adv Gastroenterol, 12, pp.1756284819874922~ (2019)
48. López-Góngora S, "Systematic review and meta-analysis : susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection", J Antimicrob Chemother, 70, pp.2447~2455 (2015)
49. Chen Q, "Randomised controlled trial : susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment", Aliment Pharmacol Ther, 49, pp.1385~1394 (2019)
50. Ong S, "Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation : a multicenter randomized controlled trial", Helicobacter, 24, pp.e12654~ (2019)
51. Liou JM, "Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota", J Gastroenterol Hepatol, 35, pp.1107~1116 (2020)
52. Lee SK, "Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy : repeated quadruple therapy as a third-line therapy", Helicobacter, 16, pp.410~414 (2011)
53. Murakami K, "Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan", J Gastroenterol, 48, pp.1128~1135 (2013)
54. Gisbert JP, "Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments(with clarithromycin and levofloxacin)for H. pylori infection", Dig Dis Sci, 59, pp.383~389 (2014)
55. Rodríguez de Santiago E, "Limited effectiveness with a 10-day bismuth-containing quadruple therapy(Pylera®)in thirdline recue treatment for Helicobacter pylori infection. A reallife multicenter study", Helicobacter, 22, pp.e12423~ (2017)
56. 임주현, "Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease", Gut and Liver, 11(2), pp.226~231 (2017), 거트앤리버 소화기연관학회협의회
57. Okimoto K, "Efficacy of levofloxacin based triple and high-dose PPI-amoxicillin dual eradication therapy for Helicobacter pylori after failures of first-and second-line therapies", Int Sch Res Notices, 2014, pp.631501~ (2014)
58. Tursi A, "Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection", J Gastrointestin Liver Dis, 21, pp.133~138 (2012)
59. Mori H, "10-Year trends in Helicobacter pylori eradication rates by sitafloxacin-based third-line rescue therapy", Digestion, 101, pp.644~650 (2020)
60. Saito Y, "Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacinresistant Helicobacter pylori", Cancers(Basel), 11, pp.116~ (2019)
61. Hirata Y, "Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen", Int J Infect Dis, 51, pp.66~69 (2016)
62. Mori H, "Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for Helicobacter pylori strains containing the gyrA mutation", Helicobacter, 21, pp.286~294 (2016)
63. Sugimoto M, "High Helicobacter pylori cure rate with sitafloxacinbased triple therapy", Aliment Pharmacol Ther, 42, pp.477~483 (2015)
64. Furuta T, "Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan", J Gastroenterol Hepatol, 29, pp.487~493 (2014)
65. Matsuzaki J, "Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first-and second-line therapies", Antimicrob Agents Chemother, 56, pp.1643~1645 (2012)
66. Hirata Y, "Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan", Int J Antimicrob Agents, 39, pp.352~355 (2012)
67. Gisbert JP, "Fourthline rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures", Aliment Pharmacol Ther, 35, pp.941~947 (2012)
68. Mori H, "Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication : a pilot study", United European Gastroenterol J, 4, pp.380~387 (2016)

관련 논문AI추천